The online reference source for the interventional NeuroRadiology, Neurology and NeuroSurgery community
Expansion of CorPath GRX into neurovascular intervention could mark first step in revolutionizing stroke treatmentWALTHAM, MA — February 14, 2019 — Corindus Vascular Robotics (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention. CorPath GRX, the second generation robotic platform, received FDA clearance for percutaneous coronary intervention (PCI) in 2016 and peripheral vascular intervention (PVI) in 2018. Upon successful FDA clearance, CorPath GRX would become the world’s first and only robotic platform indicated for use in PCI, PVI and neurovascular intervention (NVI).
February 26, 2019
An agreement study
February 20, 2019
Medtronic said today it won expanded FDA approval for its Pipeline Flex embolization device.
February 11, 2019
Sim&Cure is honoured and proud to announce that Sim&Size reached 1500 patient cases at the end of 2018! We are thankful to our clients and partners Medtronic, Microvention, Cerenovus, Balt, Phenox, Stryker and to each neurointerventionist that choose Sim&Size to support their interventional cases.Sim&Cure starts 2019 with a lot of excitement; working on new Sim&Size releases, waiting for the FDA approval, develop the use of Sim&Size in new countries and still more cases to come on the Asian, African, American and European continent! www.sim-and-cure.com
January 31, 2019
Approval Puts RAPID in a Class of Its Own for Diagnosing and Treating StrokeMENLO PARK, Calif. - iSchemaView, the worldwide leader in advanced imaging for stroke, today announced that the FDA has cleared the RAPID neuroimaging platform for use in selecting stroke patients who are likely to benefit from endovascular thrombectomy (clot removal). Specifically, this additional clearance means that RAPID CT-Perfusion and RAPID MR-Perfusion can be used by physicians to aid in the selection of acute stroke patients with known occlusion of the internal carotid artery or proximal middle cerebral artery for a clot removal procedure. RAPID is the only imaging platform approved for selecting stroke patients for clot removal.
January 17, 2019
The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysmsAliso Viejo, CA. – January 7, 2019 – MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB System is the first and only PMA approved device in the new category of intrasaccular flow disruptors for aneurysm embolization. (The WEB System was developed by Sequent Medical, Inc. and Sequent was acquired by Terumo in 2016).
January 11, 2019
Company Also Receives European CE Mark Approval for Novel Stroke Technology Designed for Difficult to Extract Blood ClotsIRVINE, Calif., Dec. 10, 2018 -- Johnson & Johnson Medical Devices Companies* today announced that its CERENOVUS business has launched the single largest global registry, the EXCELLENT Registry, to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device, a next generation stent retriever used in mechanical thrombectomy.
December 11, 2018
Minneapolis, Minnesota (October 29, 2018) - Society of Vascular and Interventional Neurology's 2018 annual meeting to showcase breakthrough technology on stroke thrombectomy offering a ray of hope for stroke patients worldwide. The results of latest clinical trials and breaking science news related to the use of vacuum aspiration for removing blood clots in stroke patients will be presented at the upcoming SVIN annual meeting in San Diego.
November 5, 2018
Paris, France, October 3rd, 2018 – BALT International announced today that it has received CE Mark for MAGIC GLUE, its next generation of cyanoacrylate liquid embolic agent.
October 18, 2018
SOFIA® Catheter; A New Device for the Revascularization of Patients with Acute Ischemic Stroke
June 12, 2018